Correction to: Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms

T. Sindou-Faurie; Christine Louis-Vahdat; E. Oueld Es Cheikh; Geoffroy Canlorbe; J.‐L. Mergui; Catherine Uzan; Henri Azaïs

doi:10.1007/s00404-020-05926-3

Correction to: Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms

T. Sindou-Faurie, Christine Louis-Vahdat, E. Oueld Es Cheikh, Geoffroy Canlorbe, J.‐L. Mergui, Catherine Uzan, Henri Azaïs

In: Archives of Gynecology and Obstetrics · 2021 · vol. 303(4) , pp. 965–966 · doi:10.1007/s00404-020-05926-3 · PMID:33415440 · W3118302475

article OA: bronze CC0

📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06+body, 2026-06-10 ⓘ

This paper corrects an error in the original publication by providing the correct Table 1, which details patient characteristics and previous therapies for menopausal symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This document is a correction notice to a previously published study evaluating the efficacy of fractional CO2 laser for vulvar and vaginal menopausal symptoms, providing the corrected content of Table 1. The corrected table reports baseline patient characteristics and prior genitourinary syndrome of menopause therapies across total participants (n=46) and two recruitment sources (university hospital n=32 vs medicine cabinet n=14), including age, BMI, hormone therapy use, hyaluronic acid, lubricants, and history of pelvic/breast cancers and treatments. The main limitation is that the correction only addresses an incorrect language version of Table 1 rather than reassessing the study’s efficacy outcomes. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,497 characters · extracted from oa-pdf · click to expand

Vol.:(0123456789)1 3 Archives of Gynecology and Obstetrics (2021) 303:965–966 https://doi.org/10.1007/s00404-020-05926-3 CORRECTION Correction to: Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms T. Sindou‑Faurie1 · C. Louis‑Vahdat2 · E. Oueld Es Cheikh1 · G. Canlorbe1 · J. L. Mergui1 · C. Uzan1 · H. Azaïs1 Published online: 7 January 2021 © Springer-Verlag GmbH Germany, part of Springer Nature 2021 The original article can be found online at https ://doi.org/10.1007/ s0040 4-020-05868 -w. * H. Azaïs [email protected] 1 Department of Gynecologic and Breast Surgery and Oncology, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, 47-83 boulevard de l’hôpital, 75013 Paris, France 2 Medicine Cabinet, 126 boulevard Saint-Germain, 75006 Paris, France Correction to: Archives of Gynecology and Obstetrics https ://doi.org/10.1007/s0040 4-020-05868 -w In the original article published, the table 1 is incorrectly published in a different language. The correct Table 1 is given below. 966 Archives of Gynecology and Obstetrics (2021) 303:965–966 1 3 Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Table 1 Patients characteristic and previous therapy for genitourinary syndrome of menopause SD standard deviation, BMI body mass index, MHT menopausal hormone therapy Total (n = 46) University Hospi- tal (n = 32) Medicine cabinet (n = 14) P Age (years): mean ± SD 57.3 ± 11.1 57.4 ± 13.5 57.3 ± 10.2 0.958 Weight (kg): mean ± SD 62.4 ± 14.2 68.7 ± 14.4 52.3 ± 5.5 0.0004 Height (cm): mean ± SD 163.1 ± 8.1 164.7 ± 8.2 161.5 ± 8.1 0.343 BMI (kg/m2): mean ± SD 23.2 ± 4.7 25 ± 4.7 20.2 ± 3.2 0.003 Menopause: n (%) 40 (87.0%) 30 (93.8%) 12 (85.7%) 0.574 MHT use: n (%) 14 (30.4%) 7 (21.9%) 7 (50%) 0.084 Local hormone therapy use: n (%) 20 (43.5%) 13 (40.6%) 7 (50%) 0.748 Hyaluronic acid use: n (%) 11 (23.9%) 5 (15.6%) 6 (42.9%) 0.065 Lubricant use: n (%) 23 (50%) 11 (34.4%) 12 (85.7%) 0.003 Breast cancer: n (%) 13 (28.3%) 13 (40.6%) 0 (0%) 0.004 Pelvic cancer: n (%) 5 (10.9%) 4 (12.5%) 1 (7.1%) 1 Pelvic radiation therapy: n (%) 3 (6.5%) 2 (6.3%) 1 (7.1%) 1 Breast radiation therapy: n (%) 11 (23.9%) 11 (34.4%) 0 (0%) 0.020 Chemotherapy: n (%) 11 (23.9%) 10 (31.3%) 1 (7.1%) 0.133 Hormone therapy: n (%) 10 (21.7%) 10 (31.3%) 0 (0%) 0.020 Premature ovarian failure: n (%) 3 (6.5%) 3 (9.4%) 0 (0%) 0.543

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex: last seen: 2026-06-04T00:00:01.174412+00:00

License: CC0 · commercial use OK